EVAX Evaxion A/S IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2023Q1*2023-03-31 | 2022Q22022-06-30 | 2022Q12022-03-31 | 2021Q4*2021-12-31 | 2021Q32021-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37,000 | $154,000 | $0 | — | — | — | — | — |
| R&D expense | $2.17M | $2.75M | $2.94M | — | $4.11M | $4.80M | $6.15M | $4.42M |
| SG&A expense | $2.21M | $1.98M | $2.74M | — | $2.15M | $1.59M | $1.57M | $1.50M |
| Operating income | -$4.34M | -$4.58M | -$5.68M | — | -$6.26M | -$6.40M | -$7.72M | -$5.91M |
| Interest expense | $202,000 | $185,000 | $177,000 | — | $225,000 | $158,000 | -$838,000 | $51,000 |
| Pretax income | -$5.03M | -$6.40M | -$5.91M | — | -$4.95M | -$6.04M | -$7.05M | -$5.67M |
| Income tax | -$195,000 | -$199,000 | -$225,000 | — | -$177,000 | -$247,000 | $1.32M | -$425,000 |
| Net income | -$4.83M | -$6.20M | -$5.68M | -$6.24M | -$4.77M | -$5.79M | -$8.37M | -$5.25M |
| EPS (basic) | -0.02 | -0.12 | -0.21 | — | -0.20 | -0.25 | — | -0.27 |
| EPS (diluted) | — | — | -0.21 | — | -0.20 | -0.25 | — | -0.27 |
| Balance sheet | ||||||||
| Cash & equivalents | $14.75M | $7.99M | $7.12M | — | $25.25M | $31.41M | $32.17M | $11.94M |
| Receivables | — | — | — | — | — | — | $1.14M | — |
| Current assets | $18.18M | $10.70M | $11.37M | — | $28.53M | $35.38M | $34.70M | $16.32M |
| PP&E, netmay include right-of-use assets (IFRS) | $3.62M | $3.90M | $4.58M | — | $4.72M | $5.11M | $5.17M | $5.16M |
| Intangibles | — | — | — | — | $85,000 | $91,000 | $93,000 | $95,000 |
| Total assets | $22.45M | $15.23M | $16.75M | — | $34.00M | $41.08M | $40.16M | $24.12M |
| Current liabilities | $5.32M | $3.82M | $4.05M | — | $4.41M | $4.69M | $4.32M | $3.92M |
| Short-term debt | $184,000 | $158,000 | $152,000 | — | $119,000 | $125,000 | $126,000 | $159,000 |
| Long-term debt | $9.03M | $8.26M | $8.08M | — | $7.34M | $7.72M | $1.04M | $1.10M |
| Total debt | $9.21M | $8.42M | $8.23M | — | $7.46M | $7.84M | $1.17M | $1.26M |
| Total liabilities | $16.22M | $13.98M | $14.22M | — | $13.85M | $14.69M | $7.73M | $7.47M |
| Shareholders' equity | $6.23M | $1.25M | $2.54M | $6.58M | $20.15M | $2.54M | $32.44M | $16.65M |
| Net debt | -$5.53M | $427,000 | $1.11M | — | -$17.80M | -$23.57M | -$31.00M | -$10.69M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | -$5.19M | -$8.19M | -$4.12M | -$6.29M |
| Capital expenditure | — | — | — | — | $83,000 | $181,000 | $176,000 | $332,000 |
| Free cash flow | — | — | — | — | -$5.27M | -$8.37M | -$4.29M | -$6.63M |
| Investing cash flow | — | — | — | — | -$77,000 | -$159,000 | -$177,000 | -$331,000 |
| Financing cash flow | — | — | — | — | -$300,000 | $7.74M | $24.65M | -$65,000 |
| Stock-based compensation | — | — | — | — | $300,000 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.